Allogeneic day 15/16 gestational fetal liver cells have a competitive engraftment advantage over adult bone marrow cells when given to fetal recipients
| . | CD4+ . | CD8+ . | CD19+ . | MAC-1+ . | Total . |
|---|---|---|---|---|---|
| 2 mo | |||||
| % Donor BM origin | 3.9 ± 0.4 | 1.1 ± 0.1 | 3.5 ± 0.2 | 0.0 ± 0.0 | 8.6 ± 0.5 |
| % Donor FL origin | 35.8 ± 1.1 | 13.4 ± 3.2 | 25.0 ± 1.3 | 4.3 ± 0.3 | 78.5 ± 1.9 |
| 4.5 mo | |||||
| % Donor BM origin | 2.8 ± 0.2 | 1.3 ± 0.1 | 3.6 ± 0.3 | 0.04 ± 0.04 | 7.8 ± 0.4 |
| % Donor FL origin | 28.2 ± 0.2 | 15.8 ± 0.5 | 23.4 ± 1.6 | 5.1 ± 0.3 | 72.4 ± 1.9 |
| 12.5 mo | |||||
| % Donor BM origin | 1.7 ± 0.4 | 0.9 ± 0.2 | 8.3 ± 1.7 | 0.0 ± 0.0 | 10.9 ± 1.9 |
| % Donor FL origin | 17.4 ± 1.9 | 12.8 ± 1.3 | 35.1 ± 2.9 | 8.4 ± 0.9 | 73.7 ± 2.5 |
| . | CD4+ . | CD8+ . | CD19+ . | MAC-1+ . | Total . |
|---|---|---|---|---|---|
| 2 mo | |||||
| % Donor BM origin | 3.9 ± 0.4 | 1.1 ± 0.1 | 3.5 ± 0.2 | 0.0 ± 0.0 | 8.6 ± 0.5 |
| % Donor FL origin | 35.8 ± 1.1 | 13.4 ± 3.2 | 25.0 ± 1.3 | 4.3 ± 0.3 | 78.5 ± 1.9 |
| 4.5 mo | |||||
| % Donor BM origin | 2.8 ± 0.2 | 1.3 ± 0.1 | 3.6 ± 0.3 | 0.04 ± 0.04 | 7.8 ± 0.4 |
| % Donor FL origin | 28.2 ± 0.2 | 15.8 ± 0.5 | 23.4 ± 1.6 | 5.1 ± 0.3 | 72.4 ± 1.9 |
| 12.5 mo | |||||
| % Donor BM origin | 1.7 ± 0.4 | 0.9 ± 0.2 | 8.3 ± 1.7 | 0.0 ± 0.0 | 10.9 ± 1.9 |
| % Donor FL origin | 17.4 ± 1.9 | 12.8 ± 1.3 | 35.1 ± 2.9 | 8.4 ± 0.9 | 73.7 ± 2.5 |
Balb/c severe combined immunodeficient fetuses at day 15/16 of gestation were injected intraperitoneally with 1 × 106 T-cell-depleted adult C57BL/6 CD45.2 bone marrow (BM) cells and 1 × 106 C57BL/6 CD45.1 fetal liver (FL) cells harvested at day 15/16 of gestation. Peripheral blood leukocytes were phenotyped at the indicated times after birth. The average percentage ± 1 SEM of cells resulting from each of the allogeneic stem cell sources is shown for each of the indicated cell lineages. n = 34 at 2 and 4.5 mo, n = 12 at 12.5 mo.